Clinical Trials Insight: 700034058
Phase of Trial: Phase I
Latest Information Update: 29 May 2008
At a glance
- Drugs CER 002 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Cerenis Therapeutics
- 29 May 2008 New trial record.
- 15 May 2008 Results have been presented in a Cerenis Therapeutics media release.